Low-grade glioma (LGG, WHO grade 2 — IDH-mutant) · None

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Track	standard
Linked regimen	`None`

ID	`IND-NF2-CARRIER-SURVEILLANCE`
Type	Indication
Status	reviewed 2026-05-20 \| pending_clinical_signoff
Diseases	`DIS-GLIOMA-LOW-GRADE`
Sources	`SRC-NCCN-CNS-2025` `SRC-NCCN-GENETIC-FAMILIAL-BREAST-OVARIAN-2025`

Notes

STUB — v0.3 NF2-related schwannomatosis + SMARCB1-schwannomatosis surveillance track. Sibling — IND-NF2-CARRIER-INTENSIFIED (aggressive plan_track). CRITICAL severity inherited from RF. Disease anchor DIS-GLIOMA-LOW-GRADE is v0.3 approximation only — flagged for v0.4 cleanup when dedicated DIS-VESTIBULAR-SCHWANNOMA / DIS-MENINGIOMA / DIS-EPENDYMOMA entities land.

Used By

Indication

IND-NF2-CARRIER-INTENSIFIED - IND-NF2-CARRIER-INTENSIFIED

Red flag

RF-NF2-SCHWANNOMATOSIS-CARRIER - Confirmed germline pathogenic / likely-pathogenic variant in NF2 (neurofibromin 2 / merli...